You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

5q deletion

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

22q11 Deletion Syndrome Trial in Philadelphia, Seattle, Toronto (NB-001, Placebo)

Recruiting
  • 22q11 Deletion Syndrome
  • Aurora, Colorado
  • +3 more
Nov 16, 2022

People Who Have Genetic Changes and Features of Autism: Simons

Recruiting
  • 16P11.2 Deletion Syndrome
  • +184 more
    • New York, New York
    • +1 more
    Jan 6, 2023

    22q11.2 Deletion Syndrome Trial in Philadelphia (NFC-1)

    Completed
    • 22q11.2 Deletion Syndrome
    • Philadelphia, Pennsylvania
      Children's Hospital of Philadelphia
    Mar 24, 2022

    Neurodevelopmental Disorders, Autism, Autism Spectrum Disorder Trial in Canada (Sertraline, Placebo)

    Not yet recruiting
    • Neurodevelopmental Disorders
    • +25 more
    • Calgary, Alberta, Canada
    • +6 more
    Oct 11, 2023

    22Q11 Deletion Syndrome, tACS Trial (at-home tACS using Starstim-Home tES)

    Not yet recruiting
    • 22Q11 Deletion Syndrome
    • tACS
    • at-home tACS using Starstim-Home tES
    • (no location specified)
    Dec 15, 2022

    22Q11 Deletion Syndrome Trial (Aware Program)

    Not yet recruiting
    • 22Q11 Deletion Syndrome
    • Aware Program
    • (no location specified)
    Apr 28, 2023

    Examining Genetic Factors That Affect Severity of 22q11.2

    Recruiting
    • DiGeorge Syndrome
    • 22q11.2 Deletion Syndrome
      • New York, New York
      • +1 more
      Jul 18, 2022

      22Q Deletion Syndrome Trial in Greenville, Brisbane, Melbourne (ZYN002)

      Active, not recruiting
      • 22Q Deletion Syndrome
      • Greenville, South Carolina
      • +2 more
      Apr 20, 2022

      22q13 Deletion Syndrome, Phelan-McDermid Syndrome Trial in New York (Insulin-Like Growth Factor-1 (IGF-1), Normal saline)

      Completed
      Has Results
      • 22q13 Deletion Syndrome
      • Phelan-McDermid Syndrome
      • Insulin-Like Growth Factor-1 (IGF-1)
      • Normal saline
      • New York, New York
        Seaver Austin Center, Icahn School of Medicine at Mount Sinai
      Apr 18, 2022

      REVLIMID® Treatment of IPSS Low- or Intermediate-1-risk

      Recruiting
      • Myelodysplastic Syndromes
      • +2 more
      • Anyang, Korea, Republic of
      • +12 more
      Apr 6, 2021

      22q11.2 Deletion Syndrome Trial in Geneva (Concerta)

      Recruiting
      • 22q11.2 Deletion Syndrome
      • Geneva, Switzerland
        Developmental imaging and psychopathology lab
      Mar 29, 2022

      22q11.2 Deletion Syndrome Trial in Geneva (Risperdal, Placebo)

      Terminated
      • 22q11.2 Deletion Syndrome
      • Geneva, Switzerland
        Developmental imaging and psychopathology lab
      Mar 29, 2022

      Children at Increased Risk for Scoliosis Development

      Recruiting
      • Adolescent Idiopathic Scoliosis
      • 22q11.2 Deletion Syndrome
      • MRI
      • +2 more
      • Utrecht, Netherlands
        UMC Utrecht
      Jun 20, 2023

      Telomeric 22Q13 Monosomy Syndrome, Tuberous Sclerosis, Hamartoma Syndrome, Multiple Trial in Chicago (Functional Behavioral

      Enrolling by invitation
      • Telomeric 22Q13 Monosomy Syndrome
      • +7 more
      • Functional Behavioral Training (FBT)
      • Positive Parenting Strategies-Treatment as Usual
      • Chicago, Illinois
        Autism Assessment Research Treatment and Services (AARTS) Center
      Nov 14, 2023

      Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7) Trial in United

      Completed
      Has Results
      • Adult Acute Basophilic Leukemia
      • +16 more
      • Little Rock, Arkansas
      • +53 more
      Jan 13, 2022

      Angelman Syndrome Trial (60 mg QD Alogabat, 40 mg QD Alogabat, 7 mg QD Alogabat)

      Not yet recruiting
      • Angelman Syndrome
      • 60 mg QD Alogabat
      • +4 more
      • (no location specified)
      Feb 1, 2023

      Trisomy 21, 18, 13 and 22q11.2 Deletion Syndrome

      Recruiting
      • Pregnancy
      • cfDNA screening
      • Tuebingen, Germany
        University Hospital Tuebingen, Department of Women's Health
      Jan 11, 2022

      22q11.2 Deletion Syndrome Trial in Lyon (neuropsychological testing, questionnaires and experimental tasks)

      Recruiting
      • 22q11.2 Deletion Syndrome
      • neuropsychological testing, questionnaires and experimental tasks
      • Lyon, Rhone Alpes, France
        Hopital Vinatier
      Jan 26, 2022

      Advanced Data Analytics in Genetic Conditions

      Not yet recruiting
      • Neurofibromatosis
      • +2 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Feb 2, 2023

        Microdeletion 3q29 Syndrome, Microduplication 3q29 Syndrome Trial in Atlanta

        Recruiting
        • Microdeletion 3q29 Syndrome
        • Microduplication 3q29 Syndrome
          • Atlanta, Georgia
            Internet-Based
          Feb 1, 2021

          Genetic Modifiers for 22q11.2 Syndrome

          Completed
          • 22q11.2 Deletion Syndrome
          • Observation
          • Syracuse, New York
            VCFS International Center
          Oct 19, 2021

          MDS, Myelodysplastic Anemia, Myelodysplastic Syndrome With Isolated Del(5Q) Trial (description of MDS pzatient cohort)

          Recruiting
          • Myelodysplastic Syndromes
          • +5 more
          • description of MDS pzatient cohort
          • Brest, France
            Chu Brest
          Oct 27, 2022

          Prenatal Examination of Deletion 22q11 Syndrome : Thymic

          Completed
          • 22q11 Deletion Syndrome Di George Syndrome
            • Nîmes, France
              CHUNimes
            Jan 26, 2021

            MDS Trial in United States (Lenalidomide, Luspatercept)

            Recruiting
            • Myelodysplastic Syndromes
            • Miami, Florida
            • +5 more
            Sep 28, 2022

            Influenza, Human Trial (FLU Q-PAN H5N8 Formulation 1, AS03B, AS03A)

            Not yet recruiting
            • Influenza, Human
            • FLU Q-PAN H5N8 Formulation 1
            • +3 more
            • (no location specified)
            Jul 27, 2023